145 related articles for article (PubMed ID: 19010160)
1. Mycophenolate mofetil monotherapy in patients who underwent liver transplantation for hepatitis C cirrhosis.
Manrique A; Jiménez C; Ortega P; Abradelo M; Gimeno A; Calvo J; Cambra F; -Sterup RL; Morales JM; Moreno E
Transplant Proc; 2008 Nov; 40(9):2962-4. PubMed ID: 19010160
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil monotherapy in liver transplantation.
Pierini A; Mirabella S; Brunati A; Ricchiuti A; Franchello A; Salizzoni M
Transplant Proc; 2005; 37(6):2614-5. PubMed ID: 16182763
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mycophenolate mofetil monotherapy in liver transplant patients with renal failure induced by calcineurin inhibitors.
Barrera Pulido L; Alamo Martínez JM; Pareja Ciuró F; Gómez Bravo MA; Serrano Díez-Canedo J; Bernal Bellido C; Suárez Artacho G; García González I; Pascasio Acevedo JM; Bernardos Rodríguez A
Transplant Proc; 2008 Nov; 40(9):2985-7. PubMed ID: 19010168
[TBL] [Abstract][Full Text] [Related]
4. Immunosuppression based on mycophenolate mofetil in stable liver transplanted patients.
Bilbao I; Castells L; Rojas L; Cancino J; Dopazo C; Castro E; Pou L; Andino R; Margarit C
Int Immunopharmacol; 2006 Dec; 6(13-14):1977-83. PubMed ID: 17161351
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.
Moreno JM; Rubio E; Gómez A; Lopez-Monclus J; Herreros A; Revilla J; Navarrete E; Sánchez Turrión V; Jimenez M; Cuervas-Mons V
Transplant Proc; 2003 Aug; 35(5):1874-6. PubMed ID: 12962831
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of monotherapy with mycophenolate mofetil in liver transplantation.
Jiménez-Pérez M; Lozano Rey JM; Marín García D; Olmedo Martín R; de la Cruz Lombardo J; Rodrigo López JM
Transplant Proc; 2006 Oct; 38(8):2480-1. PubMed ID: 17097974
[TBL] [Abstract][Full Text] [Related]
7. Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience.
Fairbanks KD; Thuluvath PJ
Liver Transpl; 2004 Sep; 10(9):1189-94. PubMed ID: 15350013
[TBL] [Abstract][Full Text] [Related]
8. A prospective randomized trial of mycophenolate mofetil in liver transplant recipients with hepatitis C.
Jain A; Kashyap R; Demetris AJ; Eghstesad B; Pokharna R; Fung JJ
Liver Transpl; 2002 Jan; 8(1):40-6. PubMed ID: 11799484
[TBL] [Abstract][Full Text] [Related]
9. Long-term mycophenolate mofetil monotherapy in combination with calcineurin inhibitors for chronic renal dysfunction after liver transplantation.
Raimondo ML; Dagher L; Papatheodoridis GV; Rolando N; Patch DW; Davidson BR; Rolles K; Burroughs AK
Transplantation; 2003 Jan; 75(2):186-90. PubMed ID: 12548120
[TBL] [Abstract][Full Text] [Related]
10. Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction.
Ponton C; Vizcaíno L; Tomé S; Otero E; Molina E; Castroagudín JF; López-Lago A; Varo Pérez E
Transplant Proc; 2010 Mar; 42(2):656-9. PubMed ID: 20304216
[TBL] [Abstract][Full Text] [Related]
11. Mycophenolate mofetil monotherapy in liver transplant recipients.
Kriss M; Sotil EU; Abecassis M; Welti M; Levitsky J
Clin Transplant; 2011; 25(6):E639-46. PubMed ID: 22007615
[TBL] [Abstract][Full Text] [Related]
12. Impact of immunosuppression minimization and withdrawal in long-term hepatitis C virus liver transplant recipients.
Manzia TM; Angelico R; Ciano P; Mugweru J; Owusu K; Sforza D; Toti L; Tisone G
World J Gastroenterol; 2014 Sep; 20(34):12217-25. PubMed ID: 25232255
[TBL] [Abstract][Full Text] [Related]
13. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction.
Koch RO; Graziadei IW; Schulz F; Nachbaur K; Königsrainer A; Margreiter R; Vogel W
Transpl Int; 2004 Oct; 17(9):518-24. PubMed ID: 15365603
[TBL] [Abstract][Full Text] [Related]
14. Four-year follow-up of a prospective randomized trial of mycophenolate mofetil with cyclosporine microemulsion or tacrolimus following liver transplantation.
Fisher RA; Stone JJ; Wolfe LG; Rodgers CM; Anderson ML; Sterling RK; Shiffman ML; Luketic VA; Contos MJ; Mills AS; Ferreira-Gonzalez A; Posner MP
Clin Transplant; 2004 Aug; 18(4):463-72. PubMed ID: 15233827
[TBL] [Abstract][Full Text] [Related]
15. Safety of mycophenolate mofetil monotherapy in patients after liver transplantation.
Kamphues C; Bova R; Röcken C; Neuhaus R; Pratschke J; Neuhaus P; Neumann UP
Ann Transplant; 2009; 14(4):40-6. PubMed ID: 20009154
[TBL] [Abstract][Full Text] [Related]
16. Influence of mycophenolate mofetil on preservation of kidney function in liver transplant patients.
Barrera-Pulido L; Espinosa-Aguilar MD; Marín D; Nuñez-Garcia F; Jiménez-Pérez M; de la Mata-Garcia M; Gómez-Bravo MA
Transplant Proc; 2010 Mar; 42(2):651-5. PubMed ID: 20304215
[TBL] [Abstract][Full Text] [Related]
17. Switch to 1.5 grams MMF monotherapy for CNI-related toxicity in liver transplantation is safe and improves renal function, dyslipidemia, and hypertension.
Orlando G; Baiocchi L; Cardillo A; Iaria G; De Liguori Carino N; De Luca L; Ielpo B; Tariciotti L; Angelico M; Tisone G
Liver Transpl; 2007 Jan; 13(1):46-54. PubMed ID: 17154392
[TBL] [Abstract][Full Text] [Related]
18. Long-term, maintenance MMF monotherapy improves the fibrosis progression in liver transplant recipients with recurrent hepatitis C.
Manzia TM; Angelico R; Toti L; Bellini MI; Sforza D; Palmieri G; Orlando G; Tariciotti L; Angelico M; Tisone G
Transpl Int; 2011 May; 24(5):461-8. PubMed ID: 21294787
[TBL] [Abstract][Full Text] [Related]
19. Anti-interleukin-2 receptor therapy in combination with mycophenolate mofetil is associated with more severe hepatitis C recurrence after liver transplantation.
Nelson DR; Soldevila-Pico C; Reed A; Abdelmalek MF; Hemming AW; Van der Werf WJ; Howard R; Davis GL
Liver Transpl; 2001 Dec; 7(12):1064-70. PubMed ID: 11753908
[TBL] [Abstract][Full Text] [Related]
20. Clinical evolution in the first 3 months of patients after liver transplantation in maintenance phase converted from mycophenolate mofetil to mycophenolate sodium due to gastrointestinal complications.
Miras M; Carballo F; Egea J; Martínez C; Alvarez-López MR; Sánchez-Bueno F; Parrilla P
Transplant Proc; 2007 Sep; 39(7):2314-7. PubMed ID: 17889175
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
